Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis.
about
The significance of different formulations of aerosolized colistin.Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road aheadColistimethate sodium for the treatment of chronic pulmonary infection in cystic fibrosis: an evidence-based review of its place in therapyElucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models.Dosing Recommendations for Continuous Venovenous Hemodiafiltration with AN69 Filter Membranes and Prismaflex DialyzersQuality control guidelines for testing gram-negative control strains with polymyxin B and colistin (polymyxin E) by standardized methods.Colistin in the 21st century.Self-assembly behavior of colistin and its prodrug colistin methanesulfonate: implications for solution stability and solubilization.Evaluating the stability of colistin and colistin methanesulphonate in human plasma under different conditions of storageStructure--activity relationships of polymyxin antibioticsfAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models.Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model.Colistin dosing and nephrotoxicity in a large community teaching hospital.Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.'Old' antibiotics for emerging multidrug-resistant bacteriaColistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa.Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii.Dosing of colistin-back to basic PK/PD.Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula.Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosingThe use of intravenous colistin among children in the United States: results from a multicenter, case seriesImpact of two-component regulatory systems PhoP-PhoQ and PmrA-PmrB on colistin pharmacodynamics in Pseudomonas aeruginosa.Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections.Pharmacokinetics of colistin in cerebrospinal fluid after intraventricular administration of colistin methanesulfonatePharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?Optimizing Polymyxin Combinations Against Resistant Gram-Negative BacteriaHuman oligopeptide transporter 2 (PEPT2) mediates cellular uptake of polymyxins.Subacute toxicity of colistin methanesulfonate in rats: comparison of various intravenous dosage regimensTreatment options for multidrug-resistant bacteria.Population pharmacokinetic analysis of colistin in burn patients.Stability of colistin methanesulfonate in pharmaceutical products and solutions for administration to patients.Polymyxin B: similarities to and differences from colistin (polymyxin E).Pharmacokinetics of four different brands of colistimethate and formed colistin in rats.Polymyxins revisited.Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria.Pharmacokinetics of colistin methanesulfonate and formed colistin in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysisNew dosing strategies for an old antibiotic: pharmacodynamics of front-loaded regimens of colistin at simulated pharmacokinetics in patients with kidney or liver disease.Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy.A Novel Chemical Biology Approach for Mapping of Polymyxin Lipopeptide Antibody Binding EpitopesIn vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy.
P2860
Q24817033-14428E6F-3610-4B2F-9325-9DFD996DBB49Q26822988-D1BFD058-2AFA-4AC6-9A0A-4477CAE24B6AQ27014993-C9F8286D-C66E-499C-B326-6299E5661A07Q33676366-EE27073E-6AB6-4731-9B48-ED3F73A34C90Q33681401-730E1ECA-8462-4410-84F1-0593D16615EAQ33825674-3C1D018E-667F-4143-9FF7-9B3EBA040D90Q33847509-987C77A6-D56A-4419-AED8-23DAAB65E2FAQ33895471-6BFF0BA1-86EE-4CC5-A55C-0C2CC4D80717Q33902534-5125EA19-4220-4CAD-BD0B-A4DD45C66D94Q34010143-E26C45B4-1580-43E7-B4D0-0EAA76DB128EQ34060378-9B4ADC8A-0EC6-4FE8-AD1C-84B17FFA932DQ34108660-0D22635A-6CD5-4A71-811A-AAB3DC31A1C9Q34150958-67A06589-235A-49EC-BFB7-CEB0FB2819A1Q34297656-626564C2-146C-4B71-B778-3F46101A9647Q34565772-AF55FBBC-BE53-483C-8DA2-8CD0F1F05D9BQ34680516-B494BA6B-D3F5-4668-AE2F-ED6457ECE06DQ35023321-3C0F628B-958E-44B4-932B-01C6E0040557Q35242165-5FA76C66-B257-4764-8149-62066E6FE7D4Q35364351-5A1AD1DE-17E3-4E7F-A6D7-EB1F39C34F9AQ35541277-1D0455A5-76EF-4A5F-978B-5706D4B68D74Q35592264-EC13DC12-ECC1-40E6-B198-FFC19AE4BD68Q36018883-8C5056CF-18C6-4EE7-857F-83698B53BE92Q36095874-EA940E97-EFAE-408B-BCD0-1A19E2E84017Q36171581-E131188B-FAAC-4C14-BB5D-69BF982618E6Q36335694-B80348FC-C59A-4BCD-9D18-AD840C45225CQ36363261-B61B2F30-A3EA-44C1-B666-E96DEF2F210EQ36455352-F5EEFF2F-CF8D-4F66-9B73-A8905C171EE7Q36482895-29DB688A-D867-44C6-A1F5-6ABE592F1DE9Q36607401-DDA6183D-5BC5-4E3B-ADCF-4EE9B4DBCD4BQ36785854-A1E2BCF4-0FCD-4834-A89F-E8A92FF19A6EQ36870716-3B472A4B-3AFA-4D7D-9AEE-03683D32B0A6Q36960059-2036C999-4B81-4E5B-9D50-9CEA5BCBE1FDQ37169946-3F710686-6B34-4226-B51E-233B7A4ACBF4Q37215935-17137F33-CDE7-4874-8DCD-57CC6C3826AFQ37274659-B448C78B-D67F-42D8-9F52-0E15302DC83CQ37544285-BEB91252-74F1-4228-ADDB-C47660A3AA5FQ37643631-D3836C3F-900C-42B1-B4BD-51B02763DCDBQ37656243-9DE2AE38-414E-494B-988A-2052D74D19F2Q37660423-D02DD5D6-B388-48E5-A7D4-03B9EC72F5CFQ37712983-A0CEFA5D-4103-4076-AB09-85114433587B
P2860
Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Steady-state pharmacokinetics ...... patients with cystic fibrosis.
@en
Steady-state pharmacokinetics ...... patients with cystic fibrosis.
@nl
type
label
Steady-state pharmacokinetics ...... patients with cystic fibrosis.
@en
Steady-state pharmacokinetics ...... patients with cystic fibrosis.
@nl
prefLabel
Steady-state pharmacokinetics ...... patients with cystic fibrosis.
@en
Steady-state pharmacokinetics ...... patients with cystic fibrosis.
@nl
P2093
P356
P1476
Steady-state pharmacokinetics ...... patients with cystic fibrosis.
@en
P2093
Christine Etherington
John Turnidge
Kingsley Coulthard
Robert Milne
Roger L Nation
Steven Conway
P304
P356
10.1093/JAC/DKG468
P407
P577
2003-10-29T00:00:00Z